Esophagogastric Junction Outflow Obstruction Is Likely to Be a Local Manifestation of Other Primary Diseases: Analysis of Single-Center 4-Year Follow-Up Data

Yan Wang, Ting Yu, Feng Zhu, Ying Xu, Yun Bao, Ling Zhang, Lin Lin, Yurong TangDiagnostics 2023 · DOI

TL;DR

This study investigates Esophagogastric Junction Outflow Obstruction (EGJOO), a motility disorder, and its relationship with Achalasia Cardia (AC). The key finding is that EGJOO is often a localized symptom of underlying organic diseases like cancer or autoimmune conditions, unlike AC which is considered a primary esophageal motility disorder. This distinction has significant implications for diagnosis and treatment.

What Problem Does This Paper Address?

Esophagogastric Junction Outflow Obstruction (EGJOO) is a poorly understood esophageal motility disorder that shares many symptoms with Achalasia Cardia (AC), such as dysphagia and regurgitation. The exact nature of EGJOO has been debated: is it a distinct entity, an early stage of AC, or a manifestation of other underlying diseases? This ambiguity makes diagnosis and treatment challenging. High-resolution manometry (HRM) has improved the classification of esophageal motility disorders, but differentiating EGJOO from AC and identifying its potential causes remains a clinical hurdle. This paper aims to clarify these distinctions by analyzing clinical characteristics, manometric findings, and treatment outcomes in patients with EGJOO and AC over a four-year follow-up period.

Methods

The researchers conducted a retrospective analysis of 149 patients (79 with AC, 70 with EGJOO) who underwent high-resolution manometry (HRM) between January 2017 and December 2018. Patients were followed up for an average of 28 months. EGJOO patients were categorized into "anatomical EGJOO" (if an underlying organic cause was identified) and "functional EGJOO." Similarly, AC patients were classified as "AC with organic disease" or "true AC."

Key data collected included:

  • Clinical characteristics: Demographics, disease duration, and symptom severity (using the Eckardt score).
  • High-Resolution Manometry (HRM) parameters: Measurements of esophageal and lower esophageal sphincter (LES) pressures and relaxations.
  • Treatment response: How patients responded to various interventions (medications, POEM, pneumatic dilation, resolution of underlying causes).
  • Follow-up data: To assess the development of new organic diseases or symptom changes.

Statistical analysis involved comparing continuous data using t-tests or Mann-Whitney U tests and categorical data using chi-square or Fisher exact tests, with a significance level of p < 0.05.

Datasets

Not discussed in the paper. The study utilized data from patients treated at a single center.

Key Insights and Ideas

  • EGJOO as a "local manifestation": The most significant insight is that EGJOO appears to be frequently a symptom of other underlying conditions, rather than a primary motility disorder like AC. This reframes how clinicians should approach EGJOO diagnosis.
  • Distinct patient profiles: EGJOO patients were generally older, had shorter disease durations, and presented with milder baseline symptoms compared to AC patients.
  • Association with serious conditions: EGJOO patients showed a significantly higher prevalence of concurrent adenocarcinoma of the esophagogastric junction (AEG) and autoimmune diseases compared to AC patients. This highlights the importance of thorough investigation for these conditions in EGJOO patients.
  • Treatment response differences: Anatomical EGJOO patients often improved when their underlying primary disease was treated. Functional EGJOO patients, on the other hand, responded well to medications or even experienced spontaneous relief. AC patients predominantly benefited from POEM.
  • HRM limitations: While HRM is crucial for diagnosis, the study found that HRM parameters alone were not sufficient to differentiate between anatomical and functional EGJOO, suggesting that clinical context and further investigations are vital.

Key Results

  • Prevalence of underlying diseases: 7.14% of EGJOO patients were diagnosed with AEG during follow-up, and 10% had concomitant autoimmune diseases, significantly higher than in AC patients (p < 0.05 for both).
  • Symptom severity: Baseline Eckardt scores were lower in EGJOO patients, particularly functional EGJOO, compared to AC patients.
  • Treatment outcomes:
    • Anatomical EGJOO: 35% achieved symptom relief through resolution of potential reasons (e.g., autoimmune disease, AEG).
  • Functional EGJOO: 68.09% experienced symptom relief with medications.
  • AC: 95.65% achieved symptom relief with POEM.
  • HRM differences: Significant differences were observed in LES basal pressure, IRP, and UES parameters between EGJOO and AC, suggesting distinct physiological mechanisms. However, no significant HRM differences were found between anatomical and functional EGJOO.

Limitations and Future Work

  • Follow-up data: Post-treatment follow-up data were not available for all EGJOO patients, as many achieved symptom relief and were unwilling to undergo further testing.
  • Predictors of response: A logistic regression analysis to identify predictors of favorable treatment responses was not performed due to a small number of patients with unfavorable outcomes.
  • Single-center study: The findings are from a single center, which may limit generalizability.

The authors suggest that for EGJOO patients, especially those with anatomical EGJOO, clinicians should consider investigating for underlying conditions like tumors, autoimmune diseases, and abnormal esophageal anatomy. They recommend close follow-up even if initial examinations are normal, and suggest that HRM, CT scans, and autoimmune status examinations can provide valuable evidence for pursuing further investigations. They also propose a diagnostic and treatment algorithm, emphasizing conservative management for anatomical EGJOO and medication-based treatment for functional EGJOO, while reserving POEM as a primary treatment for AC.

Summary updated

Abstract

Concurrent AEG and autoimmune diseases are more likely in EGJOO than in AC. A considerable part of EGJOO may be the early manifestation of an organic disease. Anatomical EGJOO patients experience symptom improvement with the resolution of primary diseases, while most functional EGJOO patients experience symptom relief with pharmacotherapy alone or even without any treatment.
BibTeX
@inproceedings{wang2023esophagogastric,
  author = {Yan Wang and Ting Yu and Feng Zhu and Ying Xu and Yun Bao and Ling Zhang and Lin Lin and Yurong Tang},
  title = {{Esophagogastric Junction Outflow Obstruction Is Likely to Be a Local Manifestation of Other Primary Diseases: Analysis of Single-Center 4-Year Follow-Up Data}},
  booktitle = {Diagnostics},
  year = {2023},
  doi = {10.3390/diagnostics13142329},
}
Figure